| |
Press Releases | Archives
2010
-
25aug
August, Wednesday 25 2010 ¬ 15:00 UTC
NexMed To Present at the Rodman & Renshaw 12th Annual Healthcare Conference
-
23aug
August, Monday 23 2010 ¬ 13:00 UTC
NexMed Receives Additional Patent Coverage for Israel
-
26jul
July, Monday 26 2010 ¬ 16:36 UTC
Mohamed Hachicha, Ph.D. Joins NexMed, Inc. as Vice President-Research and Development for NexMed, USA
-
07jul
July, Wednesday 07 2010 ¬ 12:30 UTC
NexMed Regains Compliance with NASDAQ Listing Requirements
-
28jun
June, Monday 28 2010 ¬ 16:09 UTC
NexMed to Present PrevOnco® Data at ILCA Annual Conference
-
24jun
June, Thursday 24 2010 ¬ 17:20 UTC
NexMed Announces First Patent Allowance for Vitaros® in Japan
-
23jun
June, Wednesday 23 2010 ¬ 17:54 UTC
NexMed Receives Screening Acceptance Letter from Health Canada for Vitaros®
-
22jun
June, Tuesday 22 2010 ¬ 13:15 UTC
NexMed Announces Appointment of Deirdre Y. Gillespie, M.D. to the Board of Directors
-
15jun
June, Tuesday 15 2010 ¬ 13:20 UTC
NexMed Announces Pre-Clinical Results Showing That Its Proprietary Calcipotriene Betamethasone Psoriasis Formulation is Bioequivalent to Talconex®
-
10jun
June, Thursday 10 2010 ¬ 9:07 UTC
NexMed Provides Update on Canadian Filing for Vitaros®
-
25may
May, Tuesday 25 2010 ¬ 21:00 UTC
NexMed Announces Expansion of Senior Business Development Team
-
17may
May, Monday 17 2010 ¬ 21:11 UTC
NexMed to Discuss P2/3 Protocol for NexACT®-Based Alprostadil Treatment for Raynaud's Syndrome with the FDA
-
12may
May, Wednesday 12 2010 ¬ 15:19 UTC
Nexmed Announces Pre-Clinical Study Showing
Vitaros® Significantly Promotes Wound Healing
-
10may
May, Monday 10 2010 ¬ 21:19 UTC
NexMed Announces Encouraging Pre-Clinical Results Showing the Ability of the NexACT® Technology to Enhance the Bioavailability of rituximab When Administered Subcutaneously
-
06may
May, Thursday 6 2010 ¬ 20:45 UTC
NexMed Expands Scientific Advisory Board with Appointment of Key Industry Leaders
-
05may
May, Wednesday 5 2010 ¬ 20:36 UTC
NexMed Announces Patent Allowance for NexACT® in Canada
-
28Apr
April, Wednesday 28 2010 ¬ 22:47 UTC
Pre-Clinical Results Show NexACT® Technology Significantly Improves Subcutaneous Delivery and Anti-Metastatic Activity of Angstrom's A6 Cancer Compound
-
27Apr
April, Tuesday 27 2010 ¬ 20:40 UTC
NexMed Appoints Dr. Stephen B. Howell, World Renowned Key Opinion Leader in Oncology as Chairman of Its Scientific Advisory Board
-
26Apr
April, Monday 26 2010 ¬ 14:11:23 UTC
NexMed Receives FDA Clearance for PrevOnco® Phase 2 Study as First-Line Therapy for HCC
-
22Apr
April, Friday 22 2010 ¬ 00:50 UTC
NexMed Files CMC Response with Health Canada for Vitaros®
-
13Apr
April, Tuesday 13 2010 ¬
15:00 UTC
NexMed and Ångstrom Pharmaceuticals to Present Data on Å6 Drug at AACR
-
09Apr
April, Friday 09 2010 ¬
13:00 UTC
NexMed Announces Expansion of Its Bio-Quant Subsidiary Facilities
-
05Apr
April, Monday 05 2010 ¬
13:15 UTC
NexMed Announces the Expansion of Its Senior Management Team
-
29Mar
March, Monday 29 2010 ¬
11:18 UTC
Nexmed Files Investigational New Drug Application with Fda for Cancer Drug Candidate
-
25Mar
March, Thursday 25 2010 ¬
14:00 UTC
NexMed, Inc. to Co-Sponsor Biotalk of Dr. Diego Miralles of Johnson & Johnson at the San Diego Biotechnology Discussion Group
-
23Mar
March, Tuesday 23 2010 ¬
17:21 UTC
NexMed, Inc. Enters into Distribution Agreement for Japan
-
17Mar
March, Wednesday 17 2010 ¬
14:00 UTC
NexMed Announces the Ability of Its NexACT® Technology to Deliver Insulin and Taxol Subcutaneously in a Depot-Like Fashion
-
17Mar
March, Wednesday 17 2010 ¬
12:30 UTC
NexMed Bolsters Its Cash Reserve with $1.4 Million Infusion from Successful Mortgage Refinancing on Its New Jersey Facility
-
09Mar
March, Tuesday 09 2010 ¬
11:06:15
Nexmed To Present At The Roth 22Nd Annual Oc Growth Stock Conference
-
08Feb
February, Monday 08 2010 ¬
14:54:29
NexMed Receives over $2.7 Million Cash Infusion
-
01Feb
February, Monday 01 2010 ¬
14:54:29
NexMed Granted Request for Continued Listing on NASDAQ
-
19Jan
January, Tuesday 19 2010 ¬
14:54:29
Nexmed Updates on Canadian Aproval Process for Vitaros
-
12Jan
January, Tuesday 12 2010 ¬
14:54:29
NexMed Announces the Ability of the NexACT® Technology to Deliver Drugs Orally and with Enhanced Bioavailability
-
08Jan
January, Friday 08 2010 ¬
10:48:29
NexMed Provides Corporate Update
2009
-
18Dec
December, Friday 18 2009 ¬
14:54:29
NexMed Granted Continued Listing on NASDAQ
-
17Dec
December, Thursday 17 2009¬
10:48:29
NexMed, Inc. Leases Its Facility in New Jersey
-
14Dec
December, Monday 14 2009 ¬
11:48:29
NexMed Closes Acquisition of Bio-Quant
-
23Nov
November, Monday 23 2009 ¬
17:40:20
NexMed, Inc. to Acquire Bio-Quant, Inc.
-
11Nov
November, Wednesday 11 2009 ¬
17:40:20
NexMed Receives Cash Infusion of $750,000
-
05Nov
November, Thursday 05 2009 ¬
17:40:20
NexMed Announces Third Quarter 2009 Financial Results Conference Call
|
